BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37568872)

  • 1. A Case of Penile Metastasis from Prostate Cancer, Identified by
    Gossili F; Langkilde NC; Zacho HD
    Diagnostics (Basel); 2023 Jul; 13(15):. PubMed ID: 37568872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesorectal Lymph Node Metastases as Index Lesion in
    Leitsmann C; Schmid M; Sahlmann CO; Trojan L; Strauss A
    Front Surg; 2021; 8():637134. PubMed ID: 33732729
    [No Abstract]   [Full Text] [Related]  

  • 4. 68Ga-PSMA-11 PET/CT Follow-Up of Patients with Prostate Cancer with Bone Metastases Who Had Reduced Bone Density after Androgen Deprivation Therapy.
    Kesler M; Druckmann I; Levine C; Kuten J; Yossepowitch O; Even-Sapir E
    Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33578990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
    Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. False-positive mpMRI and true-negative
    Tang Y; Yang J; Zhou C; Li J; Hu S
    Transl Androl Urol; 2022 Apr; 11(4):561-566. PubMed ID: 35558264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological predictors of positive
    Aydin AM; Haberal B; Artykov M; Bilen CY; Yazici S
    Ann Nucl Med; 2019 May; 33(5):326-332. PubMed ID: 30778860
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Akdemir EN; Tuncel M; Akyol F; Bilen CY; Baydar DE; Karabulut E; Ozen H; Caglar M
    World J Urol; 2019 May; 37(5):813-821. PubMed ID: 30151600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
    Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
    Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective intra-individual comparison of [
    Lawal IO; Mokoala KMG; Mahapane J; Kleyhans J; Meckel M; Vorster M; Ebenhan T; Rösch F; Sathekge MM
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):134-142. PubMed ID: 32424485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with
    Ettala O; Malaspina S; Tuokkola T; Luoto P; Löyttyniemi E; Boström PJ; Kemppainen J
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):665-673. PubMed ID: 31879814
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Fassbind S; Ferraro DA; Stelmes JJ; Fankhauser CD; Guckenberger M; Kaufmann PA; Eberli D; Burger IA; Kranzbühler B
    Ann Nucl Med; 2021 Oct; 35(10):1109-1116. PubMed ID: 34185262
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Haidar M; Abi-Ghanem AS; Moukaddam H; Jebai ME; Al Zakleet S; Al Rayess S; Akkawi AR; Kassas M; Tamim H; Hajj AE; Estrada-Lobato E; Osman MM; Shamseddine A
    Sci Rep; 2022 Nov; 12(1):20500. PubMed ID: 36443430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection Rate of
    Brumberg J; Beckl M; Dierks A; Schirbel A; Krebs M; Buck A; Kübler H; Lapa C; Seitz AK
    Biomedicines; 2020 Nov; 8(11):. PubMed ID: 33217931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT.
    Caglar M; Tuncel M; Yildiz E; Karabulut E
    Ann Nucl Med; 2020 Dec; 34(12):932-941. PubMed ID: 32975741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate penile metastasis: Incidence and imaging pattern on
    Tatkovic A; McBean R; Schoeman J; Wong D
    J Med Imaging Radiat Oncol; 2020 Aug; 64(4):499-504. PubMed ID: 32449823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Prospective Study on [
    Harsini S; Fallahi B; Karamzade Ziarati N; Razi A; Amini E; Emami-Ardekani A; Fard-Esfahani A; Kardoust Parizi M; Farzanehfar S; Beiki D
    Asia Ocean J Nucl Med Biol; 2021; 9(2):101-110. PubMed ID: 34250139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report: PSMA PET/CT addresses the correct diagnosis in a patient with metastatic prostate cancer despite negative core biopsies and mpMRI. A diagnostic challenge.
    Vetrone L; Cuzzani G; Mei R; Zanoni L; Bertaccini A; Bianchi L; Castellucci P; Gaudiano C; Cappelli A; Giunchi F; Fanti S
    Front Oncol; 2023; 13():1101221. PubMed ID: 36824128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?
    Leitsmann C; Thelen P; Schmid M; Meller J; Sahlmann CO; Meller B; Trojan L; Strauss A
    Int Braz J Urol; 2019; 45(3):459-467. PubMed ID: 30901173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.